UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Using Technology to Maintain the Education of Residents During the COVID-19 Pandemic

Journal of surgical education, 2020-07, Vol.77 (4), p.729-732

2020

Volltextzugriff (PDF)

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Breast cancer research and treatment, 2020-06, Vol.181 (2), p.391-401

2020

Volltextzugriff (PDF)

Rectal Trauma: Evidence-Based Practices

Clinics in colon and rectal surgery, 2018-01, Vol.31 (1), p.017-023

2018

Volltextzugriff (PDF)

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Clinical immunology (Orlando, Fla.), 2019-04, Vol.201, p.48-54

2019

Volltextzugriff (PDF)

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence – Implications for vaccine trial design

Clinical immunology (Orlando, Fla.), 2018-10, Vol.195, p.28-35

2018

Volltextzugriff (PDF)

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39’: An analysis of safety and immune response

Clinical immunology (Orlando, Fla.), 2018-07, Vol.192, p.6-13

2018

Volltextzugriff (PDF)

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

The American surgeon, 2017-04, Vol.83 (4), p.117-119

2017

Volltextzugriff (PDF)

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

The American surgeon, 2017-04, Vol.83 (4), p.e117

2017

Volltextzugriff (PDF)

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

The American surgeon, 2017-04, Vol.83 (4), p.e117

2017

Volltextzugriff (PDF)

Initial Safety and Production Efficacy of a Autologous Tumor Lysate Loaded Yeast Cell Wall Particle Vaccine

Journal of the American College of Surgeons, 2019-10, Vol.229 (4), p.S267-S267

2019

Volltextzugriff (PDF)

A Novel, Social-Media-Based Platform for Daily Practice Questions on In-Training Examination

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.S239-S240

2020

Volltextzugriff (PDF)

A novel student‐centered nutrition medicine education model

The FASEB journal, 2012-04, Vol.26 (S1)

2012

Volltextzugriff (PDF)

Abstract CT208: Prior vaccination with the autologous Tumor Lysate Particle Loaded Dendritic Cell (TLPLDC) Vaccine may impact clinical outcomes in melanoma patients treated with systemic therapies and re-vaccination

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT208-CT208

2019

Volltextzugriff (PDF)

Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e21025-e21025

2019

Volltextzugriff (PDF)

Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6536-6536

2020

Volltextzugriff (PDF)

Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.1-1

2019

Volltextzugriff (PDF)

Abstract CT150: Initial analysis of open-label administration of autologous tumor lysate (TL) + dendritic cells (DC) vaccine (TLPLDC) in melanoma patients who recurred during a phase IIb adjuvant vaccine trial

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT150-CT150

2018

Volltextzugriff (PDF)

Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors

Journal of the American College of Surgeons, 2017-10, Vol.225 (4), p.S23-S24

2017

Volltextzugriff (PDF)

Subgroup Analysis of the Interim Results of a Prospective, Randomized, Double Blinded, Placebo Controlled, Phase IIb Trial of the Autologous TLPLDC Vaccine in Stage III/IV (Resected) Melanoma Patients to Prevent Recurrence

Journal of the American College of Surgeons, 2018-10, Vol.227 (4), p.S249-S249

2018

Volltextzugriff (PDF)

A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.TPS201-TPS201

2018

Volltextzugriff (PDF)

Immunologic efficacy of E39 & E39' vaccination in a phase I/IIa trial in ovarian and endometrial cancer patients

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.75-75

2018

Volltextzugriff (PDF)

Abstract CT036: Early trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in ovarian cancer patients

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT036-CT036

2017

Volltextzugriff (PDF)

Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT162-CT162

2017

Volltextzugriff (PDF)

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions

Expert review of clinical immunology, 2017-03, Vol.13 (3), p.235-245

2017

Volltextzugriff (PDF)

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3088-3088

2017

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(33)
Buchkapitel
(1)

Sprache

Englisch
(34)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Using Technology to Maintain the Education of Residents During the COVID-19 Pandemic

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Rectal Trauma: Evidence-Based Practices

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence – Implications for vaccine trial design

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39’: An analysis of safety and immune response

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

Vicarious Contrast Excretion with Prolonged Retention Causing Biliary Colic

Initial Safety and Production Efficacy of a Autologous Tumor Lysate Loaded Yeast Cell Wall Particle Vaccine

A Novel, Social-Media-Based Platform for Daily Practice Questions on In-Training Examination

A novel student‐centered nutrition medicine education model

Abstract CT208: Prior vaccination with the autologous Tumor Lysate Particle Loaded Dendritic Cell (TLPLDC) Vaccine may impact clinical outcomes in melanoma patients treated with systemic therapies and re-vaccination

Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma

Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma

Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial

Abstract CT150: Initial analysis of open-label administration of autologous tumor lysate (TL) + dendritic cells (DC) vaccine (TLPLDC) in melanoma patients who recurred during a phase IIb adjuvant vaccine trial

Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors

Subgroup Analysis of the Interim Results of a Prospective, Randomized, Double Blinded, Placebo Controlled, Phase IIb Trial of the Autologous TLPLDC Vaccine in Stage III/IV (Resected) Melanoma Patients to Prevent Recurrence

Immunologic efficacy of E39 & E39' vaccination in a phase I/IIa trial in ovarian and endometrial cancer patients

Abstract CT036: Early trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in ovarian cancer patients

Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting

Suchergebnisse filtern